Akero Therapeutics shares are trading lower after the company reported reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin.
Portfolio Pulse from Benzinga Newsdesk
Akero Therapeutics reported a 36-week analysis of its Phase 2b SYMMETRY study evaluating the efficacy and safety of its lead product candidate efruxifermin. Following the news, the company's shares are trading lower.
October 10, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akero Therapeutics' shares are trading lower after the company reported a 36-week analysis of its Phase 2b SYMMETRY study on efruxifermin.
The company's shares are trading lower following the announcement of the 36-week analysis of its Phase 2b SYMMETRY study. This suggests that the market may have had negative reactions to the results of the study, impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100